SCHEMBL2368971

SCHEMBL2368971

CNC(=O)Cc1nc(NCc2ccccn2)c2c(-c3ccccc3)c(C)sc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PRKCI P41743 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 2/20 0.42
ATM Q13315 1/20 0.42
LMNA P02545 3/20 0.41
ALDH1A1 P00352 2/20 0.41
CSNK2A2 P19784 3/20 0.41
CSNK2A1 P68400 3/20 0.41
CSNK2B P67870 2/20 0.41
TNF P01375 1/20 0.40
MAPK1 P28482 1/20 0.40
NOD1 Q9Y239 1/20 0.40
POLB P06746 2/20 0.40
KCNA5 P22460 2/20 0.40
JAK2 O60674 1/20 0.40
IGF1R P08069 1/20 0.40
PIM1 P11309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369196 0.93 SMN1; SMN2 (0.42) KCNH2MEN1KMT2APRKCISMN1; SMN2
SCHEMBL2368222 0.89 PRKCI (0.41) PRKCISMN1; SMN2HTTLMNAALDH1A1
SCHEMBL3387832 0.88 ALDH1A1 (0.45) KCNH2MEN1KMT2APRKCISMN1; SMN2
SCHEMBL3382804 0.86 DYRK1A (0.46) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL2368922 0.85 KCNH2 (0.48) KCNH2MEN1KMT2APRKCISMN1; SMN2
SCHEMBL2368488 0.83 TNF (0.59) KCNH2SMN1; SMN2HTTLMNAALDH1A1
SCHEMBL2369234 0.82 ALDH1A1 (0.50) MEN1KMT2APRKCISMN1; SMN2HTT
SCHEMBL3385287 0.81 PRKCI (0.51) KCNH2MEN1KMT2APRKCISMN1; SMN2
SCHEMBL3382594 0.81 KCNH2 (0.49) KCNH2MEN1KMT2APRKCISMN1; SMN2
SCHEMBL3382770 0.81 ALDH1A1 (0.41) MEN1KMT2APRKCISMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 KCNH2 6/4885MEN1 265/4885KMT2A 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.